Publication
November 18, 2026
IAM-C1, a Potent and Selective Dual CDK2/CDK4 Inhibitor, Demonstrates Robust Antitumor Activity and a Favorable Preclinical Tolerability Profile
Let's work together
Leverage the Iambic discovery process for your program. Reach out to us at partnerships@iambic.ai.
Contact us